A Post-marketing Observational Study of Cell Therapy for Chronic Wounds

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A post-marketing multi-center observational study to provide data describing the safety and effectiveness of CUREXCELL™ as it is applied in a real-life setting for treatment in patients with chronic and/or refractory wounds.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds

NCT01113307

Wounds

COMPLETED

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

NCT01421966

Lower Extremity Chronic Ulcers in Diabetics

COMPLETED PHASE3

Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers

NCT02130310

Chronic Venous Leg Ulcers

UNKNOWN PHASE3

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

NCT00330265

Foot Ulcer Diabetes

UNKNOWN PHASE2

Use of Santyl Within an Accountable Care Organization

NCT02716519

Pressure Ulcer Foot Ulcer, Diabetic

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic wounds can be categorized into two main groups: (a) chronic ulcers, such as diabetic foot ulcers, venous leg ulcers and pressure (decubitus) ulcers (b) post-operative or traumatic, difficult-to-heal wounds, some of which may be infected such as sternal wound infections following cardiac surgery or wounds following abdominal or orthopedic surgery. Age, peripheral vascular disease, infection, diabetes mellitus, auto-immune dis., obesity, cardiac disease, cardiac failure, malnutrition, immunological deficiencies, steroid treatment, bed confinement and prolonged operation time are among the causes of wound repair delay or failure and often results in considerable morbidity and mortality. In addition, these wounds lengthen hospital stays, significantly increase the cost of care, and negatively impact the quality of life of both the patients and care giversCurrently available wound care products include various dressings, ointments, gels, antiseptic agents and devices. These products are intended to supply a suitable environment for wound healing (e.g. moist environment, particular factors required for the healing process), but they do not provide an adequate solution for this growing problem of chronic wounds.

Macrocure has developed an advanced cellular therapy for wound healing named Curexcell™. Curexcell™ not only provides the natural environment for wound healing, but also ensures that the appropriate cell activities and factor secretions are maintained as required during each of the stages of wound healing. The product contains primed/activated Monocytes, Neutrophils and Lymphocytes derived from whole blood unit, which are key role players in the normal natural wound healing process. The cells are injected locally into the wound bed.

The proposed study is a post-marketing observational study (PMOS) in which the decision to use Curexcell™ for treatment of patients with chronic and/or refractory wounds are made by local physicians. Curexcell™ will be administered to the patient in accordance with the Instructions for Use.

In this PMOS, there is no control by the investigator with respect to patients, duration and frequency of follow-up and the method by which patients are managed in general. This design truly reflects real-life circumstances.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wounds

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CureXcell treated

Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment

CureXcell

Intervention Type BIOLOGICAL

The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CureXcell

The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic and/or refractory wounds that have been referred by their physician for CUREXCELLTM treatment
* Signed consent form

* Patients with chronic lower extremity ulcers (on malleoli and below) and diabetes mellitus
* Signed the blinding guessing test section of the consent form
* Were not treated in the past by CureXcell

Exclusion Criteria

* Patients with known or suspected present malignancy (except for successfully treated basal cell carcinoma) within the past 3 years.
* Patients with gangrene
* Patients for whom amputation or a complete resection of the infection site is planned component of treatment
* Patients simultaneously participating in any interventional clinical trial
* Patients with any other known or suspected condition that may jeopardize adherence to registry protocol requirements

Eligible Sex

ALL

Accepts Healthy Volunteers

No